Hims & Hers Health stock price prediction: Weak momentum flags further downside risk

Traders Union
All News
Stocks
Hims & Hers slides 6.77% today

Highlights

Hims & Hers Health faces a securities class action lawsuit over alleged improper sharing of consumer health data and misleading practices.
The legal proceedings introduce elevated regulatory and litigation risk, increasing investor caution and weighing on market momentum.
Shares of Hims & Hers Health dropped 6.77% to $27.68, trading below short- and medium-term moving averages, with bearish indicators signaling a likely range of $26.14 to $29.22 in coming sessions.

Litigation risk pressures sentiment as class action advances

Multiple law firms have announced that shareholders of Hims & Hers Health, Inc. have until November 2, 2026, to seek lead plaintiff status in a securities class action lawsuit concerning alleged improper sharing of consumer health data and misleading business practices, according to Globenewswire. The disclosure of these legal proceedings introduces heightened regulatory and litigation risk, which can exert additional caution on investor behavior and pressure market sentiment. This development is likely contributing to recent negative momentum around the stock.

Bearish momentum intensifies as technical indicators confirm weakness

Technically, HIMS has slipped below the MA-20 and MA-50 moving averages but remains above the MA-200, highlighting key support at longer-term trendlines. The Ichimoku Kijun sits at $28.41 and acts as immediate resistance. Momentum indicators including MACD and ADX both signal strong bearish pressure, while RSI and CCI indicate the asset is in sell or oversold territory. There is some divergence in the oscillators, with Stochastic RSI showing neutrality, yet both Bull/Bear Power and the Awesome Oscillator confirm seller dominance in the intraday time frame.

Downside bias persists as price tests volatile trading range

In the short term, HIMS is expected to trade within a volatile range of $26.14 to $29.22. The probability remains high for continued downside action, with limited chances of a bullish reversal. Price consolidation between support and resistance is the baseline outlook, but a break above $28.41 would trigger a bullish scenario, whereas falling below $26.14 would open the door for further declines.

Anton Kharitonov, expert at Traders Union, sees Hims & Hers Health facing increased downside risk amid legal headwinds and confirmed bearish momentum. He notes that the stock has lost key short- and medium-term technical levels while litigation over alleged data mishandling has clearly soured market sentiment. Kharitonov remains cautious until there is a break of immediate resistance at $28.41. "Base case remains pressure towards the lower end of the range — unless $28.41 is reclaimed, I see limited appetite for upside here."

Previously it was reported that Hims & Hers Health faced increased scrutiny and short-term selling pressure due to ongoing securities litigation and legal concerns. The current session further underscores the impact of these risks as price action tests lower support levels, making a potential break below $26.14 an important downside risk to monitor.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.